Jacobs Levy Equity Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Jacobs Levy Equity Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-28,791	Closed	-$32K	–	1097
2022 Q4	$32K	Sell	28,791 -1,559	-5%	-$2.22K	﹤0.01%	932
2022 Q3	$71K	Sell	30,350 -247,681	-89%	-$877K	﹤0.01%	962
2022 Q2	$842K	Sell	278,031 -37,835	-12%	-$184K	0.01%	785
2022 Q1	$2.15M	Buy	315,866 +48,834	+18%	+$348K	0.01%	611
2021 Q4	$2.23M	Buy	+267,032	New	+$2.2M	0.01%	599
2021 Q3	–	Sell	-126,857	Closed	-$863K	–	1156
2021 Q2	$863K	Sell	126,857 -1,128	-0.9%	-$9.37K	0.01%	768
2021 Q1	$1.31M	Buy	127,985 +27,242	+27%	+$298K	0.01%	680
2020 Q4	$705K	Sell	100,743 -82,094	-45%	-$639K	0.01%	800
2020 Q3	$1.49M	Buy	182,837 +2,089	+1%	+$13K	0.02%	572
2020 Q2	$1.25M	Buy	180,748 +5,999	+3%	+$32.4K	0.01%	626
2020 Q1	$830K	Buy	174,749 +37,854	+28%	+$218K	0.01%	670
2019 Q4	$1.2M	Buy	136,895 +53,729	+65%	+$290K	0.01%	651
2019 Q3	$277K	Buy	83,166 +21,400	+35%	+$85.7K	﹤0.01%	793
2019 Q2	$306K	Buy	61,766 +46,266	+298%	+$246K	﹤0.01%	812
2019 Q1	$96K	Buy	+15,500	New	+$74.9K	﹤0.01%	931

Other funds holding JNCE

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

ACM

Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Jacobs Levy Equity Management's JNCE Position: Q1 2023 in Review

Jacobs Levy Equity Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 28,791 shares — an estimated $32K sold.

Jacobs Levy Equity Management first reported a position in JNCE in Q1 2019 and held it in 15 quarters. The position peaked at $2.23M in Q4 2021. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

Jacobs Levy Equity Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Jacobs Levy Equity Management sold 28,791 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $32K.
Jacobs Levy Equity Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2019 and held it in 15 quarters.
Jacobs Levy Equity Management's Jounce Therapeutics, Inc. Common Stock position peaked at $2.23M in Q4 2021.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2023, filed 15 May 2023.